STOCKHOLM, April 11, 2019
STOCKHOLM, April 11, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has updated its financial calendar, the interim report for Q2 2019 have been moved to 28 August.
The dates for future reports and the AGM are shown below. Oncopeptides will also host a webcast on the same day as the interim reports are published.
For more information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46-70-853-72-92
This information was submitted for publication at 10.00 CET, 11 April 2019
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen, a novel peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in a global pivotal Phase 3 trial and in three additional supporting clinical trials. Oncopeptides' headquarters is located in Stockholm, Sweden and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
More information is available on www.oncopeptides.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release - Updated financial calendar Oncopeptides